Lancet Oncology, 20, 1273-1285 Lancet oncology, 20(9), 1273-1285. Elsevier Science The Lancet Oncology, 20(9), 1273-1285 PORTEC study group 2019, ' Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3) : patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial ', The Lancet Oncology, vol. 20, no. 9, pp. 1273-1285 . https://doi.org/10.1016/S1470-2045(19)30395-X The Lancet Oncology Lancet Oncology, 20(9), 1273-1285. ELSEVIER SCIENCE INC Lancet Oncology, 20, 9, pp. 1273-1285
International Journal of Radiation Oncology-Biology-Physics, 109(4), 975-986. ELSEVIER SCIENCE INC International Journal of Radiation Oncology, Biology, Physics, 109, 975-986 International Journal of Radiation Oncology Biology Physics, 109(4), 975-986. Elsevier Science International Journal of Radiation Oncology, Biology, Physics, 109(4), 975-986. ELSEVIER SCIENCE INC International Journal of Radiation Oncology, Biology, Physics, 109, 4, pp. 975-986 International journal of radiation oncology, biology, physics, 109(4), 975-986. Elsevier
New England Journal of Medicine, 377(19), 1836-1846. MASSACHUSETTS MEDICAL SOC New England journal of medicine, 377(19), 1836-1846. Massachussetts Medical Society New England Journal of Medicine, 377(19), 1836-1846. MASSACHUSETTS MEDICAL SOCIETY
The Lancet Oncology The Lancet Oncology, 19(1), 27-39 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) & Clarke, M 2018, ' Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials ', Lancet Oncology, vol. 19, no. 1, pp. 27-39 . https://doi.org/10.1016/S1470-2045(17)30777-5 Lancet Oncology, 19(1), 27-39. Lancet Publishing Group LANCET ONCOLOGY